Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial

Abstract

The STOP-NIDDM trial was an international, double-blind, placebo-controlled randomised study in people with impaired glucose tolerance (IGT). They were treated with an α-glucosidase inhibitor, acarbose, to prevent diabetes; the overall number needed to treat (NNT) was 11.

In a secondary analysis, we considered the impact of single traits and overall metabolic syndrome (MetS) respectively on risk of diabetes and NNT respectively.

In all, there were 1,368 patients. They were followed up for 3.3 years, and the prevalence of MetS was 61%. Multivariate analysis revealed treatment group 2-hour (post-challenge) plasma glucose, glycosylated haemoglobin (HbA_1C), triglycerides and leukocyte count as independent predictors. The annual incidence of diabetes in the placebo group with MetS was 18.7% vs. 11.2% in patients without MetS; the corresponding figures in the acarbose group were 13.5% and 9.4%, respectively. The NNT in patients was 5.8 in patients with MetS and 16.5 in those without MetS.

In conclusion, most single traits and overall MetS label a very high-risk group in people with IGT. People with MetS reach a NNT to prevent development of new diabetes with acarbose of 5.8.

Trial-Number: NCT00629213//ClinicalTrials.gov

Keywords

acarbose impaired glucose tolerance metabolic syndrome primary prevention risk factors

References

1. Zimmet P , Shaw J , Alberti KG. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 2003;20:693–702.

2. Unwin N , Shaw J , Zimmet P , Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19:708–23.

3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (ATP III). JAMA 2001;285:2486–97.

4. Alberti KG , Zimmet P , Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the IDF. Diabet Med 2006;23:469–80.

5. Boyko EJ , de Courten M , Zimmet PZ , Chitson P , Tuomilehto J , Alberti KG. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care 2000;23:1242–8.

6. Meigs JB , Williams K , Sullivan LM. Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care 2004;27:1417–26.

7. Orchard TJ , Temprosa M , Goldberg R et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611–19.

8. Hanson RL , Imperatore G , Bennett PH , Knowler WC. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes 2002;51:3120–7.

9. Laaksonen DE , Lakka HM , Niskanen LK , Kaplan GA , Salonen JT , Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002;156:1070–7.

10.

10. Lorenzo C , Okoloise M , Williams K , Stern MP , Haffner SM. The metabolic syndrome as predictor of type 2 diabetes. Diabetes Care 2003;26:3153–9.

11.

11. Grundy SM , Cleeman JI , Daniels SR et al. Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52.

12.

12. Puls W Keup U , Krause HP , Thomas G , Hoffmeister F. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwissenschaften 1977;65:536–7.

13.

13. Chiasson JL , Josse RG , Gomis R , Hanefeld M , Karasik A , Laakso M. STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072–7.

14.

14. Chiasson JL , Josse RG , Gomis R , Hanefeld M , Karasik A , Laakso M. STOP-NIDDM Trail Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486–94.

15.

15. Alberti KG , Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–53.

16.

16. Ilanne-Parikka P , Eriksson JG , Lindström J et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention study. Diabetes Care 2008;31:805–07.

17.

17. Alexander CM , Landsman PB , Teutsch SM , Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;25:1210–14.

18.

18. Hanefeld M , Koehler C , Gallo S , Benke I , Ott P. Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol 2007;26:6–13.

19.

19. Gimeno Orna JA , Lou Arnal LM , Molinero Herguedas E , Boned Julian B , Portilla Cordoba DP Metabolic syndrome as a cardiovascular risk factor in patients with type 2 diabetes. Rev Esp Cardiol 2004;57:507–13.

20.

20. Sattar N , Gaw A , Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414–19.

21.

21. Wilson PW , Meigs JB , Sullivan L , Fox CS , Nathan DM , D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068–74.

22.

22. Lorenzo C , Williams K , Hunt KJ , Haffner SM. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30:8–13.

23.

23. Festa A , D'Agostino R Jr , Howard G , Mykkänen L , Tracy RP , Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2000;104:42–7.

24.

24. Chen J , Wildman RP , Hamm LL , Muntner P , Reynolds K , Whelton PK , He J; 3rd National Health and Nutrition Examination Survey . Association between inflammation and insulin resistance in U.S. non-diabetic adults: results from the 3rd National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2960–8.

25.

25. Vozarova B , Weyer C , Lindsay RS , Pratley RE , Bogardus C , Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:455–61.

26.

26. Knowler WC , Barrett-Connor E , Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.

27.

27. Tuomilehto J , Lindstrom J , Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–50.

28.

28. Hanefeld M , Cagaty M , Petrowitsch T , Neuser D , Petzinna D , Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Euro Heart J 2004;25:10–16.

29.

29. Buchanan TA. How can we prevent type 2 diabetes?. Diabetes 2007;56:1502–07.

30.

30. van de Laar FA , Lucassen PL , Akkermans RP , van de Lisdonk EH , Rutten GE , van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;18:CD003639.